Research programme: anticoagulants - Verseon

Drug Profile

Research programme: anticoagulants - Verseon

Alternative Names: Thrombin inhibitors - Verseon; VE 1902; VE 2851; VE-DTIs

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Verseon
  • Class Anticoagulants
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute coronary syndromes; Stroke; Venous thrombosis

Most Recent Events

  • 15 Nov 2017 Verseon plans a clinical trial for VE 2851 in 2018
  • 15 Nov 2017 Preclinical data in Cardiovascular disorders presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
  • 15 Nov 2017 Verseon plans a phase I trial for VE 1902 in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top